CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

54.09 -3.25 (-5.66%)

Delayed Quote Updated: 3:51 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

37 38 Next >

Why Is CRISPR Therapeutics (CRSP) Stock Moving Today? ↗

June 09, 2023

CRISPR Therapeutics (CRSP) stock is on the move Friday after the company revealed data from its CLIMB-111 and CLIMB-121 clinical trials.

Via InvestorPlace

Crispr Stock Slips; The FDA Could Approve The First CRISPR-Based Gene-Editing Drug In Just Six Months ↗

June 09, 2023

The agency said it will make an approval decision on Crispr's exa-cel in December.

Via Investor's Business Daily

Wall Street Loves These 3 Growth Stocks -- Should You? ↗

June 09, 2023

Analysts think all three of these stocks could soar.

Via The Motley Fool

Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress

June 09, 2023

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Can This Gene-Editing Stock Deliver 10X Returns? ↗

June 08, 2023

Buying shares of Intellia Therapeutics might be a smart move.

Via The Motley Fool

CRISPR Therapeutics: A Galaxy's Worth of Deep Value ↗

May 31, 2023

Wall Street is at max pessimism with this biotech, which might be a big mistake.

Via The Motley Fool

3 Disruptors I Love Right Now ↗

May 30, 2023

These stocks could deliver huge returns as the companies transform the economy.

Via The Motley Fool

FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

June 08, 2023

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? ↗

June 08, 2023

Today, CRISPR has reached an important turning point.

Via The Motley Fool

Cathie Wood Is Buying the SEC Lawsuit Dip in Coinbase (COIN) Stock ↗

June 07, 2023

Coinbase and the crypto industry at large is at war with regulators. But Cathie Wood is still buying shares of COIN stock.

Via InvestorPlace

Why Are Gene Editing Stocks EDIT, NVTA, CRSP Up Today? ↗

June 06, 2023

Gene editing stocks are up today on news that Editas Medicine will present clinical data on June 12. Here's what this means for the sector.

Via InvestorPlace

CRISPR Therapeutics Earnings Perspective: Return On Capital Employed ↗

May 23, 2023

Via Benzinga

Analyst Expectations for CRISPR Therapeutics's Future ↗

May 23, 2023

Via Benzinga

Is CRISPR Therapeutics Stock a Buy Now? ↗

May 13, 2023

The clinical-stage biotech company has been on the rise.

Via The Motley Fool

3 Top Healthcare Stocks to Buy for June ↗

June 06, 2023

These stocks have what it takes to deliver long-term growth.

Via The Motley Fool

Prediction: These 2 Stocks Could Double In the Next Year ↗

May 28, 2023

It would be a continuation of solid recent performances.

Via The Motley Fool

3 No-Brainer Stocks to Buy for Under $100 Right Now ↗

May 27, 2023

These stocks might not remain under $100 for too much longer.

Via The Motley Fool

2 Supercharged Stocks to Buy With $100 ↗

May 27, 2023

These stocks are climbing in the double digits.

Via The Motley Fool

2 Top Trends to Invest $5,000 in Right Now ↗

May 25, 2023

Renewable energy and gene-editing medical therapies are poised to grow exponentially.

Via The Motley Fool

Better Growth Stock: CRISPR Therapeutics vs. Teladoc Health ↗

May 25, 2023

Both stocks are recovering after big losses last year.

Via The Motley Fool

A Good Week For The Market But A Pause In The Biotech Rally ↗

May 22, 2023

Healthcare stocks have been lagging in 2023 with the XLV down 1.97% MTD and 3.34% YTD with CVS and UNH contributing to the weakness.

Via Talk Markets

Cathie Wood Just Sold CRISPR Therapeutics Stock. Here's Why You Should Consider Buying It ↗

May 21, 2023

Her investing thesis for holding it is probably the same as ever.

Via The Motley Fool

Cathie Wood Is Buying This Biotech Stock Like Wildfire, But Should You? ↗

May 21, 2023

It's facing a few issues that are practically guaranteed to affect shareholder returns.

Via The Motley Fool

3 Biotech Stocks That Are Revolutionizing Healthcare in 2023 ↗

May 19, 2023

Here are three of the best biotech stocks to buy; each is on the verge of significant breakthroughs that may send the price higher.

Via InvestorPlace

Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings

May 18, 2023

Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets.

Via MarketBeat

2 Stocks You'll Be Glad You Bought at These Prices ↗

May 17, 2023

Bear markets create opportunities to buy high-growth stocks at discounted valuations.

Via The Motley Fool

2 Soaring Growth Stocks That Could Rocket Even Higher ↗

May 16, 2023

One of these stocks is up 57% this year, and the other one has more than tripled already.

Via The Motley Fool

Why These 3 Nasdaq Stocks Were Glowing Green This Week ↗

May 11, 2023

These three biopharmaceutical stocks rocketed higher this week.

Via The Motley Fool

Devon Energy, CRISPR Therapeutics, And Bullish On Berkshire Succession: CNBC's 'Final Trades' ↗

May 10, 2023

On CNBC’s "Halftime Report Final Trades," Joseph Terranova of Virtus Investment Partners said CRISPR Therapeutics AG (NASDAQ: CRSP) reported strong

Via Benzinga

Why CRISPR Therapeutics Stock Is on Fire Today ↗

May 09, 2023

Thanks to the gene-editing pioneer having a pipeline chock-full of deep value and a possible regulatory approval on tap, investors are bidding up shares today.

Via The Motley Fool

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

37 38 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.